DDInter1853 DDInter228
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of [vitamin A] (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant, and free radical-scavenging activities. It has been used in dermatology for many years to treat various skin conditions ranging from acne to wrinkles [A257474,A258185] and activates nuclear receptors to regulate epithelial cell growth and differentiation.[A257474,A257629,A257609] Tretinoin is given orally to treat acute promyelocytic leukemia and topically to treat skin conditions such as acne.[L45389,L34869,L45384]
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission. The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care. Importantly, bleomycin - a highly toxic agent - was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease.
Tretinoin {u} (Compound) resembles {v} (Compound) Isotretinoin
Isotretinoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Tretinoin {u} (Compound) resembles {v} (Compound) Isotretinoin
Isotretinoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Tretinoin {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Tretinoin {u} (Compound) resembles {v} (Compound) Acitretin
Acitretin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Tretinoin {u} (Compound) resembles {v} (Compound) Isotretinoin
Isotretinoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Alpelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Tretinoin {u} (Compound) downregulates {v} (Gene) ST6GALNAC2
ST6GALNAC2 {u} (Gene) is upregulated by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Tretinoin {u} (Compound) resembles {v} (Compound) Isotretinoin
Isotretinoin {u} may lead to a major life threatening interaction when taken with {v} Sarecycline
Sarecycline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Tretinoin {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Tretinoin {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Tretinoin {u} (Compound) upregulates {v} (Gene) KEAP1
KEAP1 {u} (Gene) is downregulated by {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Tretinoin (Compound) resembles Isotretinoin (Compound) and Iso
Tretinoin (Compound) resembles Isotretinoin (Compound) and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tretinoin (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tretinoin (Compound) resembles Acitretin (Compound) and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tretinoin (Compound) resembles Isotretinoin (Compound) and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tretinoin (Compound) downregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is upregulated by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tretinoin (Compound) resembles Isotretinoin (Compound) and Isotretinoin may lead to a major life threatening interaction when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tretinoin (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tretinoin (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Tretinoin (Compound) upregulates KEAP1 (Gene) and KEAP1 (Gene) is downregulated by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin